| New α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors B Barlaam, TG Bird, C Lambert-van der Brempt, D Campbell, SJ Foster, ... Journal of medicinal chemistry 42 (23), 4890-4908, 1999 | 143 | 1999 |
| AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade … DM Hickinson, T Klinowska, G Speake, J Vincent, C Trigwell, J Anderton, ... Clinical Cancer Research 16 (4), 1159-1169, 2010 | 138 | 2010 |
| Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically LC Riches, AG Trinidad, G Hughes, GN Jones, AM Hughes, ... Molecular cancer therapeutics 19 (1), 13-25, 2020 | 117 | 2020 |
| The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino … KG Pike, B Barlaam, E Cadogan, A Campbell, Y Chen, N Colclough, ... Journal of medicinal chemistry 61 (9), 3823-3841, 2018 | 103 | 2018 |
| Quinazoline derivatives as antiproliferative agents BC Barlaam, LFA Hennequin, CT Halsall US Patent 7,838,530, 2010 | 101 | 2010 |
| Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective … B Barlaam, S Cosulich, S Degorce, M Fitzek, S Green, U Hancox, ... Journal of Medicinal Chemistry 58 (2), 943-962, 2015 | 89 | 2015 |
| Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel U Hancox, S Cosulich, L Hanson, C Trigwell, C Lenaghan, R Ellston, ... Molecular cancer therapeutics 14 (1), 48-58, 2015 | 88 | 2015 |
| Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors R Ducray, P Ballard, BC Barlaam, MD Hickinson, JG Kettle, DJ Ogilvie, ... Bioorganic & medicinal chemistry letters 18 (3), 959-962, 2008 | 80 | 2008 |
| Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML I Morgado-Palacin, A Day, M Murga, V Lafarga, ME Anton, A Tubbs, ... Science signaling 9 (445), ra91-ra91, 2016 | 73 | 2016 |
| Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase SL Degorce, B Barlaam, E Cadogan, A Dishington, R Ducray, SC Glossop, ... Journal of medicinal chemistry 59 (13), 6281-6292, 2016 | 73 | 2016 |
| Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist JS Scott, TA Moss, A Balazs, B Barlaam, J Breed, RJ Carbajo, ... Journal of Medicinal Chemistry 63 (23), 14530-14559, 2020 | 67 | 2020 |
| Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies B Barlaam, R Casella, J Cidado, C Cook, C De Savi, A Dishington, ... Journal of Medicinal Chemistry 63 (24), 15564-15590, 2020 | 65 | 2020 |
| Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology JW Johannes, L Almeida, B Barlaam, PA Boriack-Sjodin, R Casella, ... ACS medicinal chemistry letters 6 (3), 254-259, 2015 | 58 | 2015 |
| Orally bioavailable and blood–brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice J Karlin, J Allen, SF Ahmad, G Hughes, V Sheridan, R Odedra, ... Molecular cancer therapeutics 17 (8), 1637-1647, 2018 | 55 | 2018 |
| Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors B Barlaam, J Anderton, P Ballard, RH Bradbury, LFA Hennequin, ... ACS Medicinal Chemistry Letters 4 (8), 742-746, 2013 | 54 | 2013 |
| Solid-phase synthesis of hydroxamic acid based TNF-α convertase inhibitors B Barlaam, P Koza, J Berriot Tetrahedron 55 (23), 7221-7232, 1999 | 49 | 1999 |
| Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors C Bardelle, B Barlaam, N Brooks, T Coleman, D Cross, R Ducray, I Green, ... Bioorganic & medicinal chemistry letters 20 (21), 6242-6245, 2010 | 45 | 2010 |
| New hydroxylamines for the synthesis of hydroxamic acids B Barlaam, A Hamon, M Maudet Tetrahedron letters 39 (43), 7865-7868, 1998 | 44 | 1998 |
| Estrogen receptor-β ligands BC Barlaam, TM Piser US Patent 6,518,301, 2003 | 43 | 2003 |
| Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I) B Barlaam, A Pape, A Thomas US Patent 7,521,453, 2009 | 42 | 2009 |
